CompletedNCT00246220
Three doses of extended-release methylphenidate for adults with ADHD
About this title
A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.
Read the official source — NCT00246220This study evaluated the safety and effectiveness of methylphenidate hydrochloride for people with ADHD.
Medication studyAges 18–65
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of methylphenidate hydrochloride for people with ADHD.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 402
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00246220
- Official title
Show the full official title
A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study To Evaluate the Safety And Efficacy Of Prolonged Release OROS Methylphenidate Hydrochloride (18, 36 and 72 mg/Day), With Open-Label Extension, In Adults With Attention Deficit/Hyperactivity Disorder
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of methylphenidate hydrochloride for people with ADHD.
Who is behind this study?
The study sponsor is Janssen Pharmaceutica N.V., Belgium.
Did this study involve medication?
Yes. The study involved medication, including methylphenidate hydrochloride.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD